

6 15 2020

Prevalence of Chemosensory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis Reveals Significant Ethnic Differences

Christopher S. von Bartheld^{a*}, Molly M. Hagen^b, Rafal Butowt^c

^a Center of Biomedical Research Excellence in Cell Biology, University of Nevada, Reno School of Medicine, Reno, Nevada, USA

^b School of Community Health Sciences, University of Nevada, Reno, Nevada, USA

^c Department of Molecular Cell Genetics, L. Rydygier Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

Key Words: Anosmia, Smell, COVID-19, SARS-CoV-2, Prevalence, Diagnosis, Hypogeusia, Taste, Ethnicity

Running Head: Prevalence of chemosensory dysfunction in COVID-19 patients

* Corresponding author:

Christopher S. von Bartheld
Center of Biomedical Research Excellence in Cell Biology
University of Nevada, Reno
Reno, NV 89557-0352 (USA)
cvonbartheld@med.unr.edu

None of the authors have any proprietary interests or conflicts of interest related to this submission.

Abstract

A significant fraction of people who test positive for COVID-19 have chemosensory deficits. However, the reported prevalence of these deficits in smell and/or taste varies widely, and the reason for the differences between studies is unclear. We determined the pooled prevalence of such chemosensory deficits in a systematic review. We searched the COVID-19 portfolio of the National Institutes of Health for all studies that reported the prevalence of smell and/or taste deficits in patients diagnosed with COVID-19. Forty-two studies reporting on 23,353 patients qualified and were subjected to a systematic review and meta-analysis. Estimated random prevalence of olfactory dysfunction was 38.5%, of taste dysfunction was 30.4% and of overall chemosensory dysfunction was 50.2%. We examined the effects of age, disease severity, and ethnicity on chemosensory dysfunction. The effect of age did not reach significance, but anosmia/hypogeusia decreased with disease severity, and ethnicity was highly significant: Caucasians had a 3-6 times higher prevalence of chemosensory deficits than East Asians. The finding of ethnic differences points to genetic, ethnicity-specific differences of the virus-binding entry proteins in the olfactory epithelium and taste buds as the most likely explanation, with major implications for infectivity, diagnosis and management of the COVID-19 pandemic.

Funding

Funding was provided by grant GM103554 from the National Institutes of Health and the “Excellence Initiative - Research University” programme at the Nicolaus Copernicus University.

Conflicts of Interests

The authors have declared no competing interests.

Author Contributions

Christopher von Bartheld and Rafal Butowt designed the study and wrote the manuscript, Molly Hagen prepared the meta-analysis, and all authors edited and approved the final version of the manuscript.

Text: 3,782 words

2 Tables

6 Figures

Introduction

The first reports of disturbances of smell and taste in COVID-19 patients emerged in February and March of 2020. Initially, these reports were anecdotal, but soon articles consistently described an increased prevalence of chemosensory deficits. Many of the earliest studies were compiled in six recent reviews (da Costa et al., 2020; Passarelli et al., 2020; Pellegrino et al., 2020; Printza and Constantinidis, 2020; Sedaghat et al., 2020; Tong et al., 2020). Two of these reviews (Passarelli et al., 2020; Tong et al., 2020) conducted a meta-analysis of 6 and 10 studies, respectively, the other four were narrative reviews (da Costa et al., 2020; Pellegrino et al., 2020; Printza and Constantinidis, 2020; Sedaghat et al., 2020). Studies reported prevalence of chemosensory dysfunction with wide ranges, between 5% and 98% for anosmia, and between 6% and 93% for taste dysfunctions (Tong et al., 2020). The reasons for differences in the prevalence reported in different studies were thought to be due to differences in the age of patients, in assessment methods, or in the severity of the disease. In addition, patient selection was thought to play a role – since some data were from hospitalized patients, others from clinic visits, and cohorts were from different countries, and data obtained with different study designs. Most studies relied on the patients' subjective impressions about sensation of smell or taste.

To gain a more comprehensive and conclusive account of the prevalence of chemosensory deficits in COVID-19, we conducted a systematic review and meta-analysis of 42 studies that reported on the chemosensory function of 23,353 patients diagnosed with COVID-19. We included preprints of not yet peer-reviewed studies, up to the posting on June 10, 2020. Because we considered a larger number of studies and larger cohort numbers than previous reviews, we provide a clearer picture of the true prevalence, and, importantly, we stratified and examined confounding variables such as age, methodology, disease severity, and ethnicity. We report that ethnicity is a significant factor. The finding of ethnic differences has important implications for the diagnosis of COVID-19, and for the management of the pandemic in countries with different ethnic populations.

Results

We adhered to the preferred reporting items for systematic reviews and meta-analyses (PRISMA), as shown in the flowchart (Fig. 1). Our search strategy retrieved 42 studies that fulfilled the inclusion criteria, reporting on 46 distinct cohorts, with prevalence information on a total of 23,353 patients from 18 different countries. Studies are from multiple countries (Lechien et al., 2020a; Qiu et al., 2020), from Italy (Giacomelli et al., 2020; Vaira et al., 2020b; Spinato et al., 2020; Vaira et al., 2020c; Gelardi et al., 2020; Meini et al., 2020; Boscolo-Rizzo et al., 2020), Germany (Streeck, 2020; Luers et al., 2020; Bertlich et al., 2020; Hornuss et al., 2020; Haehner et al., 2020; Qiu et al., 2020), France (Klopfenstein et al., 2020; Lechien et al., 2020b; Zayet et al., 2020; Tudrej et al., 2020; Qiu et al., 2020), Spain (Beltran-Corbellini et al., 2020; Borobia et al., 2020; Abalo-Lojo et al., 2020; Romero-Sanchez et al., 2020), USA (Yan et al., 2020a; Yan et al., 2020b; Kaye et al., 2020; Menni et al., 2020), China (Mao et al., 2020; Qiu et al., 2020), Korea (Rabin, 2020; Lee et al., 2020), Singapore (Wee et al., 2020; Kai Chua et al., 2020), UK (Patel et al., 2020; Menni et al., 2020), Canada (Carignan et al., 2020; Lee et al., 2020), Iceland (Gudbjartsson et al., 2020), Israel (Levinson et al., 2020), Iran (Moein et al. 2020), Holland (Tostmann et al., 2020), Switzerland (Speth et al., 2020), Belgium (Lechien et al., 2020c), Greece (Tsivgoulis et al., 2020), and Japan (Komagamine and Yabuki, 2020). The included studies are listed chronologically and by geographic region (East Asia vs Europe/ Middle East/ North America) in Table 1. Whether some patients had both, smell and taste dysfunction was stated explicitly only in a fraction of studies or was apparent from the numbers given (19/46 cohorts, Table 1).

The overall estimated random prevalence of smell loss among COVID-19 patients, calculated from a total of 38 cohorts containing 12,154 persons, was 38.48% [95% confidence interval (CI), 28.33-49.74%]. The meta-analysis indicated that between-study variability in prevalence of smell loss was high ($\tau^2 = 1.99$; heterogeneity $I^2 = 98.9\%$ with $Q = 3363.4$, $df = 37$ and $p = 0.999$; Higgins and Thompson, 2002) and examination of the funnel plots, as expected, showed evidence of publication bias (Fig. 2A). The 30 cohorts with information on taste loss contained a total of 9,589 patients. The overall

estimated random prevalence of taste loss among COVID-19 patients was 30.37% [95% CI, 20.07-43.11%]; the analysis indicated that between-study variability was high ($\tau^2 = 2.2449$; heterogeneity $I^2 = 98.8\%$ with $Q = 2341.1$, $df = 29$ and $p = 0.999$; Fig. 2B). When smell and taste loss were combined, the overall estimated random prevalence obtained from 23,353 patients in 46 cohorts was 50.20% [95% CI, 41.51-58.88%]; the analysis showed high heterogeneity with some publication bias (Fig. 2C).

There was a significant difference between countries with majority East Asians and countries with majority Caucasians in the prevalence of smell, taste and any chemosensory dysfunction. Ethnicity was tested for all three subgroups (loss of smell, loss of taste, and loss of smell and/or taste) and was highly significant in all three categories with $p \leq 0.0006$ (Figs. 3A-C). There were 33 studies available on smell loss in Caucasians and five studies on East Asians. Ethnicity of participants explained a significant amount of heterogeneity in smell loss ($Q = 11.9$, $df = 1$, $p = 0.0006$; Fig. 3A). The estimated random prevalence of smell loss was 43.2% [95% CI, 31.9-55.3%] for Caucasians and 15.1% [95% CI, 8.3-25.7%] for East Asians (Fig. 3A). The estimated prevalence of patients with loss of taste was 38.3% [95% CI, 27.0-51.0%] among Caucasians and significantly lower, only 6.4% [95% CI, 5.7-51.0%], among East Asians ($Q = 65.87$, $df = 1$, $p < 0.0001$; Fig. 3B). Overall estimates of chemosensory deficits were nearly three times higher for Caucasians than East Asians and also showed high heterogeneity and evidence of publication bias (Figs. 2C and 3C). Differences in chemosensory deficits between East Asians and Caucasians are further illustrated in Figure 4, with the prevalence shown in a world heat map, with the cohort size indicated by the size of the circles, and in the bar graphs in Figure 5.

Disease severity. As a measure of disease severity, we used information about hospitalization rates within cohorts. The weighted regression analyses showed a significant negative influence of the percent of the cohort that was hospitalized during data collection on the proportion of patients with loss of smell, taste, and loss of smell and/or taste (Fig. 6). The beta coefficients for the effect of disease severity on loss of smell ($b = -0.0261$, $p = 0.0018$) and taste ($b = -0.0262$, $p = 0.0035$) showed that both

were reported less frequently in cohorts as the number of individuals in the cohort who were hospitalized increased. This result was even more highly significant when loss of smell and taste were combined ($b = -0.0216$, $p < 0.0001$; Fig. 6, Table 2). Accordingly, patients with severe COVID-19 report fewer smell/taste dysfunctions.

Age. The subgroup tests for the effect of cohort age on smell loss showed some indication of a negative association ($b = -0.0562$, $p = 0.0568$), while tests for the effect of cohort age on taste showed none ($b = -0.0076$, $p = 0.8336$; Table 2), and a significant negative association was found when loss of smell and taste were combined ($b = -0.0532$, $p = 0.0148$) suggesting that increasing age may result in a lower reporting of loss of sensory deficits in general.

Methodology. The subgroup test to compare studies that used subjective or objective measures for loss of sensory function was possible only for Caucasians (there were too few studies for East Asians), and it showed no significant differences (in all cases $p \geq 0.1564$). For loss of smell, studies that used objective measures had an estimated random prevalence of 59.66% [95% CI, 27.16-85.43%] while those that used subjective measures had a prevalence of 42.22% [95%CI, 30.54-54.84%]. For loss of taste, the prevalence among the studies with objective measures was no different than among those with subjective measures ($q = 2.01$, $p = 0.1564$), with an estimated random prevalence of 25.99% [95% CI, 12.52-46.29%] and 43.12% [CI 95%, 29.99-57.28%], for objective vs. subjective measures. When the two endpoints were combined, the resulting prevalence for objective measures was 69.68% [95%CI, 44.95-86.61%], which again was not significantly different from that of subjective measures (56.85% [95%CI, 48.41-64.91%]; $q = 1.00$, $p = 0.3168$). Sample sizes were as follows: smell: objective measures = 6, subjective measures = 25; taste: objective measures = 4, subjective measures = 20; smell and/or taste: objective measures = 6, subjective measures = 31.

Nasal congestion/rhinorrhea. If the anosmia was caused by nasal congestion, as is common in cases of viral infection, then most, if not all COVID-19 patients with anosmia would be expected to have nasal congestion/rhinorrhea. However, our data shows that

a weighted mean of 58.6% of COVID-19 patients with anosmia did not have nasal congestion/ obstruction or rhinorrhea, based on n= 17 studies with a total cohort size of 4,121, consistent with the conclusion of a previous report (Lechien et al., 2020d).

Duration of chemosensory dysfunction. Based on the studies that provided such information, the average duration of smell dysfunction was 9.03 days \pm 1.32 (SEM, n= 9 studies with a total cohort number of 2,826), and 12.64 \pm 2.51 days for taste dysfunction (n=4 studies with total cohort number of 293). Duration of smell dysfunction appears shorter, but duration of taste dysfunction is based on a small number of studies (n=4).

Possibility of bias. The majority of the studies are cross-sectional, retrospective observational studies, and therefore, recollection bias may be present. Most studies are similar to those previously graded as “moderate risk of bias” (Tong et al., 2020; see also da Costa et al., 2020). Potential weaknesses are that measures mostly were not validated (Pellegrino et al., 2020), but it has to be considered that data were collected during an unprecedented pandemic when using more time-consuming assessment tools was not possible due to increased risk of virus spreading. The sample size for East Asian studies was small, but with $n \geq 4$, it was sufficient for each of the reported comparisons (Fu et al., 2011).

Discussion

The literature on the prevalence of chemosensory dysfunctions in COVID-19 has been evolving at a rapid pace. In the first two months of the COVID-19 pandemic, such deficits were considered a rare occurrence (Chen et al., 2020; Guan et al., 2020; Mao et al., 2020; Wang et al., 2020; reviewed in da Costa et al., 2020). The first report of smell and taste dysfunction that recognized this condition as a much more prevalent symptom (66.7% of COVID-19 patients) was on March 16th, 2020 by a German virologist (Streeck, 2020). The majority of subsequent studies have confirmed such a high prevalence outside of East Asia (Table 1; Fig. 3).

Compared with previous systematic reviews and meta-analyses (da Costa et al., 2020; Passarelli et al., 2020; Pellegrino et al., 2020; Printza and Constantinidis, 2020; Sedaghat et al., 2020; Tong et al., 2020), our review considers a much larger number of studies and cohort numbers. We did not include the study by Bagheri et al. (2020), because subjects in this cohort did not have COVID-19 diagnoses and therefore did not meet the inclusion criteria, although many of the cases likely were related to COVID-19 (Gane et al., 2020). The study by Bagheri et al. (2020) also failed the inclusion criteria of the meta-analysis by Passarelli et al., 2020, but was erroneously included in their analysis.

Why are chemosensory deficits rare in East Asians with COVID-19 compared to Caucasians?

Some researchers have commented on a possible difference in the frequency of chemosensory deficits between East Asians and Caucasians with COVID-19 (Lechien et al., 2020a; Lavato et al., 2020; Qiu et al., 2020). With the much more extensive datasets considered in our review (16,817 Caucasians and 6,536 East Asians), we show that there indeed is a significant difference in prevalence between these two populations: 3-fold higher for smell, 6-fold higher for taste, and 3-fold higher for smell and/or taste impairment in Caucasians (Fig. 5). Why is there such a difference? It is unlikely that such differences are due to the evolution of the SARS-CoV-2 virus itself. Studies have failed to identify recent virus mutations that increase viral transmission/

infectivity (van Dorp et al., 2020). As pointed out by Lechien et al., 2020a, the differences in the prevalence of chemosensory dysfunction may be due to ethnic differences in the frequency of variants of the ACE2 virus entry protein. Variations in the ACE2 protein can change virus binding by up to 20-fold (Li et al., 2005), and glycosylation sites relevant to the binding may be tissue-specific (Bilinska et al., 2020). ACE2 variants are genetically determined and they are known to differ in frequency between Europeans and East Asians (Benetti et al., 2020; Cao et al., 2020; Strafella et al., 2020; Williams et al., 2020). If Caucasians have more often an ACE2 variant expressed in the olfactory epithelium (presumably in the sustentacular cells of the olfactory epithelium, Bilinska et al., 2020; Butowt and von Bartheld, submitted), then these cells may bind SARS-CoV-2 with higher affinity, resulting in anosmia, whereas East Asians may have less of these ACE2 variants, and therefore will more rarely have anosmia as part of the COVID-19 symptoms.

Since the nasal epithelium has a larger viral load than respiratory epithelium (Zou et al., 2020) – and the nasal epithelium has increased expression of entry proteins for the virus (Bilinska et al., 2020) – this ethnic difference has potentially far-reaching implications for infectivity, spread of the virus (frequency of asymptomatic super-spreaders, Oran and Topol, 2020), and therefore for successful management of the pandemic. The frequency of ACE2 variants may make it more difficult in some ethnicities to control the pandemic, and easier in other ethnicities. The presence of different ACE2 variants in the nose may, in part, explain the more rapid spread of COVID-19 in Caucasians and Hispanics, as compared to East Asians, in addition to the well-known cultural differences in strategies of containment and attitudes about social distancing and the use of protective measures such as face masks.

Technical aspects and confounding variables

Methodology. Most studies rely on the subject telling the researcher about their subjective impressions. A relatively small number of studies (7/42) used objective tests to assess chemosensory dysfunction (Moein et al., 2020; Vaira et al., 2020c; Qiu et al., 2020; Bertlich et al., 2020; Hornuss et al., 2020; Lechien et al., 2020c; Tsivgoulis et al., 2020). When smell and taste was objectively tested, the percentage of subjects with

dysfunction increased in some of those studies (Moein et al., 2020; Pellegrino et al., 2020), but in one of these studies, 38% of subjective olfactory loss could not be objectively confirmed (Lechien et al., 2020c). In our analysis, the difference in prevalence between studies with objective vs subjective measures did not reach significance, however, the number of studies using objective measures was small. Self-reporting of anosmia is thought to be relatively accurate (90%, Wehling et al., 2011), so using subjective recall to obtain data on chemosensory deficits appears to be a valid approach, and, in many instances, it is the only feasible way of data collection during a raging pandemic.

Olfaction vs. taste. Some of the studies reporting on smell and taste impairment did not examine taste dysfunction separately from smell dysfunction, but rather asked patients about „smell and/or taste dysfunction.” The pooled prevalence of chemosensory dysfunction that we report is likely an underestimate, because many studies reported only how many patients had smell deficits and how many had taste deficits, but they did not report on the potential overlap (there were patients who had both types of chemosensory dysfunction in at least 19/46 cohorts). Those cases were listed in our review conservatively, meaning that we did not simply add all cases with smell dysfunction to those with taste dysfunction, because we know that there is overlap in a substantial fraction of patients (Table 1). Nevertheless, there is no doubt that a large fraction of COVID-19 patients (including otherwise asymptomatic carriers) have chemosensory deficits. Olfaction is used for tasting food (culinary experience) and it can be difficult to subjectively separate the two modalities (Pellegrino et al., 2020). Since most studies asked about *changes* to chemosensory perception, subjects with pre-existing loss of smell or taste would not have been included and would not have given false positives; some studies actively excluded patients with a history of pre-existing anosmia or ageusia.

Age. Previous investigators have noted that smell and taste dysfunctions appeared to be more frequent in the younger age groups of COVID-19 patients (e.g., Giacomelli et al., 2020). Our results are consistent with this finding, although significance was reached only for the category “smell and/or taste.” Reduction of smell with age is a well-

known phenomenon (Doty and Kamath, 2014), but the sudden loss of function coincident with COVID-19 would still be noticeable in the older population.

Duration: Our pooled analysis, based on 9 studies, revealed that the mean duration of the anosmia is 9 days. This relatively short time has implications for the pathogenetic mechanism: It seems too short for a functional recovery if such a recovery involved death and regeneration of olfactory neurons, since their replacement by stem cells alone takes 9-10 days (Schwob et al., 1995; Schwob, 2002). Alternative mechanisms, not requiring neuron death, that may explain the transient anosmia include a support-cell mediated dysfunction of the olfactory epithelium (Heydel et al., 2013) or a virus-induced short-lasting immune response (Butowt and Bilinska, 2020), although the extent of inflammation in the olfactory epithelium in response to SARS-CoV-2 is still unclear (Vaira et al., 2020b; Torabi et al., 2020).

Methods

We followed the PRISMA guidelines for systematic searches and meta-analyses (Moher et al., 2009). We searched the COVID-19 Portfolio of the National Institutes of Health (<https://icite.od.nih.gov/covid19/search/>) with the key words „anosmia”, „smell,” or „taste” on and before June 10, 2020, resulting in 1,103 records, including preprints posted prior to peer review. We also examined and included any relevant references within, and citations of, screened records. Inclusion criteria were that the paper was a novel report of the prevalence of smell and/or taste impairment in patients verified to have COVID-19. We accepted all studies that reported original and quantitative data on prevalence of chemosensory deficits in human subjects, either obtained by questioning the subjects, by chart review, or by objective chemosensory testing. We excluded from our quantitative analysis case reports, reports that did not provide exact quantitative information, reviews only, and reports of cohorts in which a COVID-19 diagnosis was not confirmed clinically or by lab tests. We also excluded studies that targeted *any* patients with chemosensory deficits, regardless of cause, because they would fail to provide a true prevalence among COVID-19 (Bagheri et al., 2020; Parma et al., 2020). We kept data on the two senses, olfaction and taste, separate, when the study reported them separately. The most common way of reporting in studies was „smell deficit,” “taste deficit,” or „smell and/or taste deficit,” and those data were separately compiled and compared. For this reason, the cohort number for olfactory deficits and gustatory deficits differs from that of the combined (smell and/or taste) category.

A pooled analysis was performed for prevalence, and significance and confidence intervals were calculated in the software „R”. We used R Studio, version 1.2.1335, for statistical analyses (R Foundation for Statistical Computing, Vienna, Austria). To calculate estimates of pooled prevalence and 95% confidence intervals, we used the R-meta package, version 4.9-5, and the metaprop function. We used random effects models with the inverse variance method for pooling and the logit transformation for proportions (DerSimonian and Laird, 1986). For ease of interpretation, we back transformed and rescaled proportions to events per 100 observations. Analysis of the heterogeneity across studies was done using the Maximum-likelihood estimator,

Higgin's I^2 and Cochran's Q method (DerSimonian and Laird, 1986; Higgins and Thompson, 2002). Publication bias was assessed by visual inspection of funnel plots (Egger et al., 1997). In all cases, significance was defined at $\alpha = 0.05$. Subgroup analysis was conducted by ethnicity, age, hospitalization rate, and methodology. Ethnicity was coded as a categorical variable with two levels: Caucasian and East Asian, because of suspected heterogeneity (Lechien et al., 2020a; Lavato et al., 2020; Qiu et al., 2020) and because these two ethnicities are the only ones for which such data are currently available. All other subgroup tests used continuous variables and the metareg function to adjust the overall meta-analysis for the subgroup. The subgroup age was a created variable that uses the center of the sample, either the mean or the median, to mark the center of the age distribution. Hospitalization rate was the percentage of subjects in the sample that were hospitalized for COVID-19.

References

Abalo-Lojo JM, Pouso-Diz JM, Gonzalez F. Taste and Smell Dysfunction in COVID-19 Patients [published online ahead of print, 2020 May 29]. *Ann Otol Rhinol Laryngol*. 2020;3489420932617. doi:10.1177/0003489420932617

Bagheri SHR, Asghari AM, Farhadi M, Shamshiri AR, Kabir A, Kamrava SK, et al., Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak. MedRxiv preprint. <https://www.medrxiv.org/content/10.1101/2020.03.23.20041889v1>

Beltrán-Corbellini Á, Chico-García JL, Martínez-Poles J, Rodriguez-Jorge F, Natera-Villalba E, Gomez-Corral J, et al. Acute-onset smell and taste disorders in the context of COVID-19: a pilot multicentre polymerase chain reaction based case-control study [published online ahead of print, 2020 Apr 22]. *Eur J Neurol*. 2020; 10.1111/ene.14273. doi:10.1111/ene.14273

Benetti E, Tita R, Spiga O, Ciolfi A, Birolo G, Bruselles A, et al. ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population. MedRxiv preprint. <https://doi.org/10.1101/2020.04.03.20047977>

Bertlich M, Stihi C, Weiss BG, Canis M, Haubner F, Ihler F. Characteristics of impaired chemosensory function in hospitalized COVID-19 Patients. Preprint in SSRN. <http://dx.doi.org/10.2139/ssrn.3576889>

Bilinska K, Jakubowska P, von Bartheld CS, Butowt R. Expression of the SARS-CoV-2 entry proteins, ACE2 and TMPRSS2, in cells of the olfactory epithelium: Identification of cell types and trends with age. *ACS Chem Neurosci*. 2020; 11(11):1555-1562. doi: 10.1021/acchemneuro.0c00210

Borobia AM, Carcas AJ, Arnalich F, Alvarez-Sala R, Montserrat J, Quintana M, et al. A cohort of patients with COVID-19 in a major teaching hospital in Europe. MedRxiv preprint. <https://doi.org/10.1101/2020.04.29.20080853>.

Boscolo-Rizzo P, Borsetto D, Spinato G, Fabbris C, Menegaldo A, Gaudio P, et al. New onset of loss of smell or taste in household contacts of home-isolated SARS-CoV-2-positive subjects [published online ahead of print, 2020 May 24]. *Eur Arch Otorhinolaryngol*. 2020; 1-4. doi:10.1007/s00405-020-06066-9

Butowt R, Bilinska K. SARS-CoV-2: Olfaction, Brain Infection, and the Urgent Need for Clinical Samples Allowing Earlier Virus Detection. *ACS Chem Neurosci*. 2020;11(9):1200-1203. doi:10.1021/acchemneuro.0c00172

Butowt R, von Bartheld CS. Anosmia in COVID-19: Underlying Mechanisms and Implications for Diagnosis and Management of the Pandemic. Invited review. *Neuroscientist* (submitted)

Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X, et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. *Cell Discov*. 2020;6:11. Published 2020 Feb 24. doi:10.1038/s41421-020-0147-1

Carignan A, Valiquette L, Grenier C, Musonera JB, Nkengurutse D, Marcil-Heguy A, et al. Anosmia and dysgeusia associated with SARS-CoV-2 infection: an age-matched case-control study [published online ahead of print, 2020 May 27]. *CMAJ*. 2020; cmaj.200869. doi:10.1503/cmaj.200869

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020; 395(10223):507-513. doi:10.1016/S0140-6736(20)30211-7

da Costa KVT, Carnaúba ATL, Rocha KW, de Andrade KCL, Ferreira SMS, Menezes PdL, Olfactory and taste disorders in COVID-19: a systematic review. *Brazil J Otorhinolaryngol*. 2020, ISSN 1808-8694, <https://doi.org/10.1016/j.bjorl.2020.05.008>.

DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7(3):177-188. doi:10.1016/0197-2456(86)90046-2

Doty RL, Kamath V. The influences of age on olfaction: a review. *Front Psychol*. 2014;5:20. Published 2014 Feb 7. doi:10.3389/fpsyg.2014.00020

Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. *Brit Med J*. 1997;315(7121):1533-1537. doi:10.1136/bmj.315.7121.1533

Fu R, Gartlehner G, Grant M, et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. *J Clin Epidemiol*. 2011;64(11):1187-1197. doi:10.1016/j.jclinepi.2010.08.010

Gane SB, Kelly C, Hopkins C. Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome? [published online ahead of print, 2020 Apr 2]. *Rhinology*. 2020;58(3):299-301. doi:10.4193/Rhin20.114.

Gelardi M, Trecca E, Cassano M, Ciprandi G. Smell and taste dysfunction during the COVID-19 outbreak: a preliminary report. *Acta Biomed*. 2020;91(2):230-231. Published 2020 May 11. doi:10.23750/abm.v91i2.9524.

Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, et al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study [published online ahead of print, 2020 Mar 26]. *Clin Infect Dis*. 2020;ciaa330. doi:10.1093/cid/ciaa330.

Guan WJ, Ni ZY, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020; 382(18):1708-1720. doi:10.1056/NEJMoa2002032

Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL, et al. Spread of SARS-CoV-2 in the Icelandic Population [published online ahead of print, 2020 Apr 14]. *N Engl J Med*. 2020; NEJMoa2006100. doi:10.1056/NEJMoa2006100

Haehner A, Draf J, Draeger S, de With K, Hummel T. Predictive value of sudden olfactory loss in the diagnosis of COVID-19. medRxiv preprint. doi: <https://doi.org/10.1101/2020.04.27.20081356>

Heydel, J-M.; Coelho, A., Thiebaud, N., Legendre, A., Bon, A-M., Faure, P., et al. Odorant-binding proteins and xenobiotic metabolizing enzymes: implications in olfactory perireceptor events. *Anat Rec (Hoboken)*. 2013;296(9):1333-1345. doi:10.1002/ar.22735

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002;21(11):1539-1558. doi:10.1002/sim.1186

Hornuss D, Lange B, Schröter N, Rieg S, Kern WV, Wagner D. Anosmia in COVID-19 patients [published online ahead of print, 2020 May 22]. *Clin Microbiol Infect*. 2020;S1198-743X(20)30294-9. doi:10.1016/j.cmi.2020.05.017

Kai Chua AJ, Yun Chan EC, Loh J, Charn TC. Acute olfactory loss is specific for Covid-19 at the Emergency Department. *Ann Emerg Med*. 2020; doi.org/10.1016/j.annemergmed.2020.05.015.

Kaye R, Chang CWD, Kazahaya K, Brereton J, Denny JC 3rd. COVID-19 Anosmia Reporting Tool: Initial Findings [published online ahead of print, 2020 Apr 28]. *Otolaryngol Head Neck Surg*. 2020;194599820922992. doi:10.1177/0194599820922992.

Klopfenstein T, Kadiane-Oussou NJ, Toko L, Royer P-Yves, Lepiller Q, Gendrin V, et al. Features of anosmia in COVID-19, *Med Mal Infect*. 2020 doi.org/10.1016/j.medmal.2020.04.006

Komagamine J, Yabuki T. Initial symptoms of patients with coronavirus disease in Japan. Preprint Research Square. doi: 10.21203/rs.3.rs-33323/v1

Lechien, J.R., Chiesa-Estomba, C.M., De Siati, D.R., Horoi, M., Le Bon, S.D., Rodriguez, A., et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study [Apr 6]. *Eur Arch Otorhinolaryngol*. 2020a; 10.1007/s00405-020-05965-1. doi:10.1007/s00405-020-05965-1 [Epub ahead of print]

Lechien JR, Cabaraux P, Chiesa-Estomba CM, Khalife M, Hans S, Martiny D, et al. (2020b) Psychophysical Olfactory Findings of Mild-to-moderate COVID-19 Patients: Preliminary Report. MedRxiv preprint. <https://doi.org/10.1101/2020.05.02.20070581>.

Lechien JR, Chiesa-Estomba CM, Hans S, Barillari MR, Jouffe L, Saussez S. Loss of Smell and Taste in 2013 European Patients with Mild to Moderate COVID-19 [published online ahead of print, 2020 May 26]. *Ann Intern Med*. 2020c;10.7326/M20-2428. doi:10.7326/M20-2428

Lechien JR, Barillari MR, Jouffe L, Saussez S. Anosmia Is a Key Symptom of COVID-19 Infection and Should Be Used as a Diagnostic Tool [published online ahead of print, 2020 May 21]. *Ear Nose Throat J*. 2020d;145561320925191. doi:10.1177/0145561320925191

Lee Y, Min P, Lee S, Kim SW. Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients. *J Korean Med Sci*. 2020; 35(18):e174. doi:10.3346/jkms.2020.35.e174

Lee DJ, Lockwood J, Das P, Wang R, Grinspun E, Lee JM. Self-reported anosmia and dysgeusia as key symptoms of COVID-19 [published online ahead of print, 2020 Jun 8]. *CJEM*. 2020;1-19. doi:10.1017/cem.2020.420

Levinson R, Elbaz M, Ben-Ami R, Shasha D, Levinson T, Choshen G, et al. (2020) Anosmia and dysgeusia in patients with mild SARS-CoV-2 infection. MedRxiv preprint. doi.org/10.1101/2020.04.11.20055483.

Li W, Zhang C, Sui J, et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. *EMBO J.* 2005;24(8):1634-1643. doi:10.1038/sj.emboj.7600640

Lovato A, Antonini A, de Filippis C. Comment on "The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis" [published online ahead of print, 2020 Jun 9]. *Otolaryngol Head Neck Surg.* 2020;194599820934761. doi:10.1177/0194599820934761

Luers JC, Rokohl AC, Loreck N, Wawer Matos PA, Augustin M, Dewald F, et al. Olfactory and Gustatory Dysfunction in Coronavirus Disease 19 (COVID-19) [published online ahead of print, 2020 May 1]. *Clin Infect Dis.* 2020; ciaa525. doi:10.1093/cid/ciaa525

Mao, L., Jin, H., Wang, M., Yu, H., Chen, S., He, Q., et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China [published online ahead of print, 2020 Apr 10]. *JAMA Neurol.* 2020; e201127. doi:10.1001/jamaneurol.2020.1127

Meini S, Suardi LR, Busoni M, Roberts AT, Fortini A. Olfactory and gustatory dysfunctions in 100 patients hospitalized for COVID-19: sex differences and recovery time in real-life [published online ahead of print, 2020 Jun 4]. *Eur Arch Otorhinolaryngol.* 2020;1-5. doi:10.1007/s00405-020-06102-8

Menni C, Valdes AM, Freidin MB, Ganesh S, El-Sayed Moustafa JS, Visconti A, et al., Real-time tracking of self-reported symptoms to predict potential COVID-19. *Nat Med.* 2020; <https://doi.org/10.1038/s41591-020-0916-2>

Moein, S.T., Hashemian, S.M.R., Mansourafshar, B., Khorram-Tousi, A., Tabarsi, P., Doty, R.L. (2020) Smell dysfunction: a biomarker for COVID-19. *Int Forum Allergy Rhinol.* 2020; Apr 17. doi:10.1002/alr.22587. [Epub ahead of print]

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *PLoS Med.* 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097

Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review [published online ahead of print, 2020 Jun 3]. *Ann Intern Med.* 2020; M20-3012. doi:10.7326/M20-3012

Parma V, Ohla K, Veldhuizen MG, Niv MY, Kelly CE, Bakke AJ, et al. (2020) More than just smell - COVID-19 is associated with severe impairment of smell, taste, and chemesthesis. MedRxiv preprint. doi.org/10.1101/2020.05.04.20090902.

Passarelli PC, Lopez MA, Mastandrea Bonaviri GN, Garcia-Godoy F, D'Addona A. Taste and smell as chemosensory dysfunctions in COVID-19 infection. *Am J Dent.* 2020;33(3):135-137.

Patel A, Charani E, Ariyanayagam D, Abdulaal A, Denny SJ, Mughal N, et al. New onset anosmia and ageusia in adult patients diagnosed with SARS-CoV-2 [published online ahead of

print, 2020 Jun 2]. *Clin Microbiol Infect.* 2020; S1198-743X(20)30303-7. doi:10.1016/j.cmi.2020.05.026

Pellegrino R, Cooper KW, Di Pizio A, Joseph PV, Bhutani S, Parma V. Corona Viruses and the Chemical Senses: Past, Present, and Future [published online ahead of print, 2020 May 14]. *Chem Senses.* 2020;bjaa031. doi:10.1093/chemse/bjaa031

Printza A, Constantinidis J. The role of self-reported smell and taste disorders in suspected COVID-19 [published online ahead of print, 2020 May 23]. *Eur Arch Otorhinolaryngol.* 2020;1-6. doi:10.1007/s00405-020-06069-6.

Qiu C, Cui C, Haufort C, Haehner A, Zhao J, Yao Q, et al. (2020) Olfactory and Gustatory Dysfunction as An Early Identifier of COVID-19 in Adults and Children: An International Multicenter Study. MedRxiv preprint. doi.org/10.1101/2020.05.13.20100198.

Rabin RC. Lost sense of smell may be a peculiar clue to coronavirus infection. *New York Times* 3 22 2020. <https://www.nytimes.com/2020/03/22/health/coronavirus-symptoms-smell-taste.html>

Romero-Sanchez CM, Diaz-Maroto I, Fernandez-Diaz E, Sanchez-Larsen A, Layos-Romero A, Garcia-Garcia J, et al. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. *Neurology.* 2020; doi: 10.1212/WNL.0000000000009937

Schwob JE. Neural regeneration and the peripheral olfactory system. *Anat Rec.* 2002;269(1):33-49. doi:10.1002/ar.10047

Schwob JE, Youngentob SL, Mezza RC. Reconstitution of the rat olfactory epithelium after methyl bromide-induced lesion. *J Comp Neurol.* 1995;359(1):15-37. doi:10.1002/cne.903590103

Sedaghat AR, Gengler I, Speth MM. Olfactory Dysfunction: A Highly Prevalent Symptom of COVID-19 With Public Health Significance [published online ahead of print, 2020 May 5]. *Otolaryngol Head Neck Surg.* 2020; 194599820926464. doi:10.1177/0194599820926464

Speth MM, Singer-Cornelius T, Obere M, Gengler I, Brockmeier SJ, Sedaghat AR. Olfactory Dysfunction and Sinonasal Symptomatology in COVID-19: Prevalence, Severity, Timing, and Associated Characteristics [published online ahead of print, 2020 May 19]. *Otolaryngol Head Neck Surg.* 2020; 194599820929185. doi:10.1177/0194599820929185

Spinato G, Fabbris C, Polesel J, Cazzador D, Borsetto D, Hopkins C, et al. Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection. *JAMA.* 2020; 323(20):2089-2090. doi:10.1001/jama.2020.6771

Strafella C, Caputo V, Termine A, Barati S, Gambardella S, Borgiani P, et al. Analysis of ACE2 genetic variability among populations highlights a possible link with COVID19-related neurological complications. Research Square preprint. Doi 10.21203/rs.3.rs-28871/v1

Streeck H. Neue Corona-Symptome entdeckt: Virologe Hendrik Streeck zum Virus. *Frankfurter Allgemeine Zeitung* 3 16 2020. <https://www.faz.net/aktuell/gesellschaft/gesundheit/coronavirus/neue-corona-symptome-entdeckt-virologe-hendrik-streeck-zum-virus-16681450.html?GEPc=s3>

Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T. The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis [published online ahead of print, 2020 May 5]. *Otolaryngol Head Neck Surg.* 2020;194599820926473. doi:10.1177/0194599820926473.

Torabi A, Mohammadbagheri E, Akbari Dilmaghani N, Bayat A-H, Fathi M, Vakili K, et al. Proinflammatory Cytokines in the Olfactory Mucosa Result in COVID-19 Induced Anosmia [published online ahead of print, 2020 Jun 11]. *ACS Chem Neurosci.* 2020;10.1021/acschemneuro.0c00249. doi:10.1021/acschemneuro.0c00249

Tostmann A, Bradley J, Bousema T, Yiek W-K, Holwerda M, Bleeker-Rovers C, et al. Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020. *Euro Surveill.* 2020;25(16):2000508. doi:10.2807/1560-7917.ES.2020.25.16.2000508

Tsivgoulis G, Fragkou PC, Delides A, Karofylakis E, Dimopoulou D, Sfikakis PP, et al. Quantitative evaluation of olfactory dysfunction in hospitalized patients with Coronavirus [2] (COVID-19) [published online ahead of print, 2020 May 25]. *J Neurol.* 2020; 1-3. doi:10.1007/s00415-020-09935-9

Tudrej B, Sebo P, Lourdoaux J, Cuzin C, Floquet M, Haller DM, et al. Self-reported loss of smell and taste in SARS-CoV-2 patients: primary care data to guide future early detection strategies. Research Square preprint. doi: 10.21203/rs.3.rs-28701/v1

Vaira LA, Salzano G, Deiana G, De Riu G. Anosmia and Ageusia: Common Findings in COVID-19 Patients. *Laryngoscope.* 2020a;130(7):1787. doi:10.1002/lary.28692

Vaira LA, Salzano G, Fois AG, Piombino P, de Riu G. Potential pathogenesis of ageusia and anosmia in COVID-19 patients. *Int Forum Allergy Rhinol.* 2020b; <https://doi.org/10.1002/alr.22593>.

Vaira LA, Deiana G, Fois AG, Pirina P, Madeddu G, de Vito A, et al. Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases. *Head Neck.* 2020c;42(6):1252-1258. doi:10.1002/hed.26204.

van Dorp L, Richard D, Tan CCS, Shaw LP, Acman M, Balloux F. No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2. Preprint bioRxiv. doi: <https://doi.org/10.1101/2020.05.21.108506>.

Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China [published online ahead of print, 2020 Mar 16]. *Clin Infect Dis.* 2020; ciaa272. doi:10.1093/cid/ciaa272

Wee LE, Chan YFZ, Teo NWY, Cherng BPZ, Thien SY, Wong HM, et al. The role of self-reported olfactory and gustatory dysfunction as a screening criterion for suspected COVID-19 [published online ahead of print, 2020 Apr 24]. *Eur Arch Otorhinolaryngol.* 2020;1-2. doi:10.1007/s00405-020-05999-5

Wehling E, Nordin S, Espeseth T, Reinvang I, Lundervold AJ. Unawareness of olfactory dysfunction and its association with cognitive functioning in middle aged and old adults. *Arch Clin Neuropsychol.* 2011;26(3):260-269. doi:10.1093/arclin/acr019

Williams FMK, Freidin MB, Mangino M, Couvreur S, Visconti A, Bowyer RCE. Self-reported symptoms of covid-19 including symptoms most predictive of SARS-CoV2 infection, are heritable. MedRxiv preprint. doi.org/10.1101/2020.04.22.20072124.

Yan CH, Faraji F, Prajapati DP, Ostrander BT, DeConde AS. Self-reported olfactory loss associates with outpatient clinical course in Covid-19 [published online ahead of print, 2020a Apr 24]. *Int Forum Allergy Rhinol.* 2020; 10.1002/alr.22592. doi:10.1002/alr.22592

Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms [published online ahead of print, 2020 Apr 12]. *Int Forum Allergy Rhinol.* 2020b;10.1002/alr.22579. doi:10.1002/alr.22579

Zayet S, Klopfenstein T, Mercier J, Kadiane-Oussou NJ, Lan Cheong Wah L, Royer PY, et al. Contribution of anosmia and dysgeusia for diagnostic of COVID-19 in outpatients [published online ahead of print, 2020 May 14]. *Infection.* 2020; 1-5. doi:10.1007/s15010-020-01442-3

Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *N Engl J Med.* 2020;382(12):1177-1179. doi:10.1056/NEJMc2001737

TABLE 1. Smell and Taste Dysfunction in COVID-19: Pooled Analysis - Chronology of Studies.

Author	First Post	Publication Date	Country	Cohort #	Age mean, m median, M	Smell disorder %	Taste disorder %	Any Chemo-Sensory disorder %	Journal or Archive
EAST ASIANS									
Mao	2 24 20	4 10 20	China	214	m 53	5.1	5.6	5.6	JAMA Neurol
Rabin		3 22 20	Korea	2000		30		30	New York Times
Wee		4 18 20	Singapore	154				22.7	Eur Arch Otorhinolaryngol
Lee		5 10 20	Korea	3191	24-59			15.3	J Korean Med Sci
Kai Chua		5 16 20	Singapore	31		22.6		22.6	Ann Emerg Med
Qiu	5 16 20		China	239	M 31	20	3	32	MedRxiv
Komagamine	6 10 20		Japan	707		8.9	8.1	17	Reseach Square
CAUCASIANS									
Streeck		3 16 20	Germany	100				66.7	Frankf Allg Zeitung
Giacomelli		3 26 20	Italy	59	M 60	5.1	10.2	33.9	Clin Infect Dis
Vaira - a		4 03 20	Italy	320				19.4	Laryngoscope
Lechien - a		4 08 20	Europe	417	m 37	85.6	88.8	88.8	Eur Arch Otorhinolaryngol
Yan - a		4 13 20	USA	59	M 46	67.8	71.2	71.2	Int Forum Allergy Rhinol
Gudbjartsson		4 14 20	Iceland	1044	m 44	11.5		11.5	NEJM
Levinson	4 14 20		Israel	42	M 34	35.7	33.3	35.7	MedRxiv
Patel	4 15 20	6 02 20	UK	141	m 46	56.7	63	63	Clin Microbiol Infect
Moein		4 17 20	Iran	60	m 47	98*		98*	Int Forum Allergy Rhinol
Moein		4 17 20	Iran	60	m 47	12	7	36*	
Klopfenstein		4 20 20	France	114	m 47	47	40.5	47	Med Mal Infect
Spinato		4 22 20	Italy	202	M 56			64.4	JAMA
Beltran-Corbellini		4 23 20	Spain	79	m 62	31.7	35.4	39.2	Eur J Neurol
Tostmann		4 23 20	Holland	79	m 38	46.8		46.8	Euro Surveill
Yan - b		4 25 20	USA	128	M 46	58.6	54.7	58.6	Int Forum Allergy Rhinol
Vaira - c		4 29 20	Italy	72	m 49	14.4*	12.5	73.6*	Head Neck
Kaye		4 29 20	most USA	237	m 40	73		73	Otolaryngol Head Neck
Luers		5 01 20	Germany	72	m 38	74	69	75	Clin Infect Dis
Bertlich	4 11 20		Germany	47	m 64	29.8*	19.1	31.9*	SSRN
Menni	4 07 20	5 11 20	UK	6452	m 41			64.8	Nature Med
Menni	4 07 20	5 11 20	USA	726	m 45			67.5	Nature Med
Hornuss	5 03 20	5 22 20	Germany	45	M 56	40*		40*	Clin Microbiol Infect
Haehner	5 03 20		Germany	34	m 39	64.7		64.7	MedRxiv
Lechien - b	5 06 20		France	28	m 44	75*	60.1	75*	MedRxiv
Borobia	5 06 20		Spain	2226	M 61	12.8		12.8	MedRxiv
Zayet		5 14 20	France	95	m 40	63.2	65.3	73.7	Infection
Tudrej	5 15 20		France	198	M 45	41.4	46.5	58.6	Research Square
Qiu	5 16 20		France	116	M 48	6	0	49	MedRxiv
Qiu	5 16 20		Germany	39	M 43	18	3	69	MedRxiv
Gelardi		5 19 20	Italy	72	m 50	11	25	83	Acta Biomed
Speth		5 20 20	Switzerland	103	m 47	61.2	65	65	Otolaryngol Head Neck
Meini	5 21 20	6 04 20	Italy	100	m 63	29	42	42	Eur Arch Otorhinolaryngol
Boscolo-Rizzo		5 26 20	Italy	54				63	Eur Arch Otorhinolaryngol
Lechien - c		5 26 20	Belgium	2013	m 40	87	56	87	Ann Int Med
Tsivgoulis		5 27 20	Greece	22	m 55	77.3	23	77.3	J Neurol
Carignan		5 29 20	Canada	134	m 57	51.5	63.4	64.9	Can Med Assoc J
Abalo-Lojo		5 29 20	Spain	131	m 50	58.8	56.5	60.3	Ann Otol Rhinol Laryngol
Romero-Sanchez		6 01 20	Spain	841	m 66	4.9	6.2	6.2	Neurology
Lee		6 08 20	Canada	56	m 38	55.4	57.1	57.1	Can J Emerg Med

TABLE 2. Subgroup test results for continuous variables: age and disease severity (percent of patients hospitalized).

Subgroup	Smell Loss			Taste Loss			Smell &/or Taste Loss		
	b	se	<i>p</i> -value	b	se	<i>p</i> -value	b	se	<i>p</i> -value
Age	-0.056	0.030	0.0568	-0.008	0.036	0.8336	-0.053	0.022	0.0148
Hospitalizations	-0.026	0.008	0.0018	-0.026	0.009	0.0035	-0.022	0.005	< 0.0001

The beta coefficients “b” show the degree of change in each outcome variable for every 1-unit of change in the predictor variable; the standard error of the beta coefficient is shown as “se”; and the *p*-value shows the likelihood that the beta coefficient is significantly different from zero. *P*-values below 0.05 indicating significance are shown in bold font.

Figure 1.




Figure 2.

Funnel Plots of the prevalence of dysfunction of smell (A), taste (B), and smell and/or taste (C) in COVID-19 patients. Each dot represents a single study with the x-axis showing the logit transformed proportion of people in each study that lost their sense of (A) smell, (B) taste, and (C) smell and/or taste; the y-axis shows the standard error.




Figure 3.

Forest plots of the prevalence of smell dysfunction (A), taste dysfunction (B), and smell and/or taste dysfunction (C) in COVID-19 patients. Estimated random proportions are shown by red boxes with 95% confidence intervals (95% CI) extending as whiskers, the overall estimated random proportion of subgroups is shown in gray, and the results for all studies combined are shown in black. Note the difference between East Asians and Caucasians.




Figure 4.

World Map of the Prevalence of any Chemosensory Deficit in COVID-19 Patients




Figure 5

Estimated random prevalence of chemosensory dysfunction in COVID-19 patients, based on ethnicity with 95% confidence intervals from meta-analysis. Note the significant difference between Caucasians and East Asians.




Figure 6

Bubble plots of subgroup tests for relationships between disease severity (the percentage of hospitalized patients in each cohort) and loss of smell (A), taste (B), and loss of smell and/or taste (C). Patients who are hospitalized (have more severe disease) report fewer chemosensory deficits.

